Trimel Pharmaceutica (TRLPF) 0.3090 $TRLPF
Trimel Announces Corporate Name Change to Acerus Pharmaceuticals Corporation
Business Wire - Tue Sep 08, 10:26AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that it has changed its corporate name to Acerus Pharmaceuticals Corporation ("Acerus", pronounced ay-SAIR-us), effective immediately.
TRL.TO: 0.43 (-0.02)
Trimel Commends FDA's Approval of the First Treatment for Female Sexual Dysfunction
Business Wire - Wed Aug 19, 4:00PM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today communicated its support of the U.S. Food and Drug Administration's (FDA) decision to approve ADDYI(TM) (flibanserin; developed by Sprout Pharmaceuticals), the first treatment option for female sexual dysfunction (FSD). Trimel is currently developing TEFINA(TM), a 'use as required', low-dose nasal testosterone gel treatment for female orgasmic disorder, a subset of FSD.
TRL.TO: 0.43 (-0.02)
Trimel Announces Second Quarter 2015 Financial Results and Highlights
Business Wire - Wed Aug 05, 6:00AM CDT
--Adjusted EBITDA(1) of ($0.4) million for Q2 2015 versus ($0.2) million in Q1 2015
TRL.TO: 0.43 (-0.02)
Trimel to Report Second Quarter 2015 Results and Host Conference Call to Update Investors
Business Wire - Wed Jul 29, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) will report its second quarter financial results for the period ended June 30, 2015 on Wednesday, August 5, 2015 before the market opens.
TRL.TO: 0.43 (-0.02)
Trimel Announces Change to Management Team
Business Wire - Mon Jul 13, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced a change to its management team. Dr. Michael Bumby will be appointed Chief Financial Officer, succeeding Mr. Kenneth Howling, who will be leaving the Company to pursue other opportunities. Dr. Bumby will join Trimel as of August 3, 2015, however Mr. Howling will remain in his role until the end of August to ensure a smooth transition.
TRL.TO: 0.43 (-0.02)
Trimel Announces Voting Results for 2015 Annual General and Special Shareholder's Meeting
Business Wire - Fri Jun 26, 3:30PM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced the voting results from its annual general and special meeting held on June 26, 2015. The total number of shares represented in person or by proxy at the meeting was 120,951,218, representing 60.21% of Trimel's total issued and outstanding shares.
TRL.TO: 0.43 (-0.02)
Trimel Confirms Next FDA Meeting on TEFINA(TM)
Business Wire - Thu Jun 11, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today reported that it has scheduled a consultation meeting with the U.S. Food and Drug Administration (FDA) to be held in August to discuss TEFINA(TM), a "use as required" nasal testosterone gel in development for female orgasmic disorder. Building on the FDA feedback received earlier this year, the objective will be to review and solicit comments on the draft protocol for a subsequent study in the TEFINA(TM) clinical program.
TRL.TO: 0.43 (-0.02)
Trimel to Present at the JMP Securities Life Sciences Conference 2015
Business Wire - Mon Jun 08, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that management is scheduled to present an overview of the Company at the JMP Securities Life Sciences Conference 2015 at the St. Regis New York on June 24, 2015 at 2:30 p.m. Eastern Time.
TRL.TO: 0.43 (-0.02)
Trimel Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun May 10, 6:01AM CDT
Trimel Announces First Quarter 2015 Financial Results and Highlights
Business Wire - Wed May 06, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today reported its financial results for the three month period ended March 31, 2015, and provided an overview of its corporate highlights. Unless otherwise noted, all dollar amounts shown in this press release are in U.S. dollars.
ENDP: 74.80 (-0.43), ENL.TO: 99.20 (-0.14), TRL.TO: 0.43 (-0.02)
Trimel to Report First Quarter 2015 Results and Host Conference Call to Update Investors
Business Wire - Thu Apr 30, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) will report its first quarter financial results for the period ended March 31, 2015 on Wednesday, May 6, 2015 before the market opens.
TRL.TO: 0.43 (-0.02)
Trimel to Present at the 2015 Bloom Burton & Co. Healthcare Investor Conference
Business Wire - Mon Apr 13, 6:22AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that management is scheduled to present an overview of the Company at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on May 4, 2015 at 3:00 p.m. Eastern Time.
TRL.TO: 0.43 (-0.02)
Trimel Announces Natesto(TM) Abstract Presentation at the 2015 Endocrine Society Annual Meeting
Business Wire - Mon Mar 09, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that an abstract highlighting the Phase III study results and therapeutic potential of NATESTO(TM), a product utilizing Trimel's licensed nasal gel technology, was featured at the Endocrine Society 97th Annual Meeting in San Diego, California on Saturday, March 7, 2015.
ENDP: 74.80 (-0.43), ENL.TO: 99.20 (-0.14), TRL.TO: 0.43 (-0.02)
Trimel Announces Filing of NATESTO(TM) With Health Canada
Marketwired - Mon Jan 26, 6:31AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that it has filed a New Drug Submission with Health Canada for NATESTO(TM) (testosterone) nasal gel for replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).
ENDP: 74.80 (-0.43), ENL.TO: 99.20 (-0.14), TRL.TO: 0.43 (-0.02)
Trimel Announces Closing of Exclusive Agreement for NATESTO(TM)
Marketwired - Tue Dec 09, 6:01AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the closing of the previously communicated agreement between its subsidiary, Trimel BioPharma SRL, and an affiliate of Endo International plc (NASDAQ: ENDP)(TSX: ENL), of which Endo has been granted the exclusive rights to market NATESTO(TM) in the United States and Mexico. Trimel has received an upfront payment of US$25 million on closing of the transaction, together with a US$5 million prepaid inventory deposit.
ENDP: 74.80 (-0.43), ENL.TO: 99.20 (-0.14), TRL.TO: 0.43 (-0.02)
Endo to Acquire Rights to Testosterone Nasal Gel Natesto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 5:00PM CST
Endo International announced that it has entered into an agreement to acquire the rights to Natesto from Trimel Pharmaceuticals Corporation.
ENDP: 74.80 (-0.43), ACT: 298.98 (-2.94), AMAG: 53.00 (-4.65)
Trimel Announces Issuance of Additional Patent Covering NATESTO(TM)
Marketwired - Tue Nov 25, 12:01PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that its technology partner Mattern Pharma AG has been granted an additional United States Patent in respect of NATESTO(TM) and its proprietary nasal gel technology. Trimel expects one or more claims in such patent to be eligible for listing in the Food and Drug Administration (FDA) Orange Book in connection with NATESTO(TM). The Orange Book is the FDA's database of Approved Drug Products with Therapeutic Equivalence Evaluations.
TRL.TO: 0.43 (-0.02)
Trimel Announces Corporate Name Change to Acerus Pharmaceuticals Corporation
Business Wire - Tue Sep 08, 10:26AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that it has changed its corporate name to Acerus Pharmaceuticals Corporation ("Acerus", pronounced ay-SAIR-us), effective immediately.
TRL.TO: 0.43 (-0.02)
Trimel Commends FDA's Approval of the First Treatment for Female Sexual Dysfunction
Business Wire - Wed Aug 19, 4:00PM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today communicated its support of the U.S. Food and Drug Administration's (FDA) decision to approve ADDYI(TM) (flibanserin; developed by Sprout Pharmaceuticals), the first treatment option for female sexual dysfunction (FSD). Trimel is currently developing TEFINA(TM), a 'use as required', low-dose nasal testosterone gel treatment for female orgasmic disorder, a subset of FSD.
TRL.TO: 0.43 (-0.02)
Trimel Announces Second Quarter 2015 Financial Results and Highlights
Business Wire - Wed Aug 05, 6:00AM CDT
--Adjusted EBITDA(1) of ($0.4) million for Q2 2015 versus ($0.2) million in Q1 2015
TRL.TO: 0.43 (-0.02)
Trimel to Report Second Quarter 2015 Results and Host Conference Call to Update Investors
Business Wire - Wed Jul 29, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) will report its second quarter financial results for the period ended June 30, 2015 on Wednesday, August 5, 2015 before the market opens.
TRL.TO: 0.43 (-0.02)
Trimel Announces Change to Management Team
Business Wire - Mon Jul 13, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced a change to its management team. Dr. Michael Bumby will be appointed Chief Financial Officer, succeeding Mr. Kenneth Howling, who will be leaving the Company to pursue other opportunities. Dr. Bumby will join Trimel as of August 3, 2015, however Mr. Howling will remain in his role until the end of August to ensure a smooth transition.
TRL.TO: 0.43 (-0.02)
Trimel Announces Voting Results for 2015 Annual General and Special Shareholder's Meeting
Business Wire - Fri Jun 26, 3:30PM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced the voting results from its annual general and special meeting held on June 26, 2015. The total number of shares represented in person or by proxy at the meeting was 120,951,218, representing 60.21% of Trimel's total issued and outstanding shares.
TRL.TO: 0.43 (-0.02)
Trimel Confirms Next FDA Meeting on TEFINA(TM)
Business Wire - Thu Jun 11, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today reported that it has scheduled a consultation meeting with the U.S. Food and Drug Administration (FDA) to be held in August to discuss TEFINA(TM), a "use as required" nasal testosterone gel in development for female orgasmic disorder. Building on the FDA feedback received earlier this year, the objective will be to review and solicit comments on the draft protocol for a subsequent study in the TEFINA(TM) clinical program.
TRL.TO: 0.43 (-0.02)
Trimel to Present at the JMP Securities Life Sciences Conference 2015
Business Wire - Mon Jun 08, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that management is scheduled to present an overview of the Company at the JMP Securities Life Sciences Conference 2015 at the St. Regis New York on June 24, 2015 at 2:30 p.m. Eastern Time.
TRL.TO: 0.43 (-0.02)
Trimel Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun May 10, 6:01AM CDT
Trimel Announces First Quarter 2015 Financial Results and Highlights
Business Wire - Wed May 06, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today reported its financial results for the three month period ended March 31, 2015, and provided an overview of its corporate highlights. Unless otherwise noted, all dollar amounts shown in this press release are in U.S. dollars.
ENDP: 74.80 (-0.43), ENL.TO: 99.20 (-0.14), TRL.TO: 0.43 (-0.02)
Trimel to Report First Quarter 2015 Results and Host Conference Call to Update Investors
Business Wire - Thu Apr 30, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) will report its first quarter financial results for the period ended March 31, 2015 on Wednesday, May 6, 2015 before the market opens.
TRL.TO: 0.43 (-0.02)
Trimel to Present at the 2015 Bloom Burton & Co. Healthcare Investor Conference
Business Wire - Mon Apr 13, 6:22AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that management is scheduled to present an overview of the Company at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on May 4, 2015 at 3:00 p.m. Eastern Time.
TRL.TO: 0.43 (-0.02)
Trimel Announces Natesto(TM) Abstract Presentation at the 2015 Endocrine Society Annual Meeting
Business Wire - Mon Mar 09, 6:00AM CDT
Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that an abstract highlighting the Phase III study results and therapeutic potential of NATESTO(TM), a product utilizing Trimel's licensed nasal gel technology, was featured at the Endocrine Society 97th Annual Meeting in San Diego, California on Saturday, March 7, 2015.
ENDP: 74.80 (-0.43), ENL.TO: 99.20 (-0.14), TRL.TO: 0.43 (-0.02)
Trimel Announces Filing of NATESTO(TM) With Health Canada
Marketwired - Mon Jan 26, 6:31AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that it has filed a New Drug Submission with Health Canada for NATESTO(TM) (testosterone) nasal gel for replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).
ENDP: 74.80 (-0.43), ENL.TO: 99.20 (-0.14), TRL.TO: 0.43 (-0.02)
Trimel Announces Closing of Exclusive Agreement for NATESTO(TM)
Marketwired - Tue Dec 09, 6:01AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the closing of the previously communicated agreement between its subsidiary, Trimel BioPharma SRL, and an affiliate of Endo International plc (NASDAQ: ENDP)(TSX: ENL), of which Endo has been granted the exclusive rights to market NATESTO(TM) in the United States and Mexico. Trimel has received an upfront payment of US$25 million on closing of the transaction, together with a US$5 million prepaid inventory deposit.
ENDP: 74.80 (-0.43), ENL.TO: 99.20 (-0.14), TRL.TO: 0.43 (-0.02)
Endo to Acquire Rights to Testosterone Nasal Gel Natesto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 5:00PM CST
Endo International announced that it has entered into an agreement to acquire the rights to Natesto from Trimel Pharmaceuticals Corporation.
ENDP: 74.80 (-0.43), ACT: 298.98 (-2.94), AMAG: 53.00 (-4.65)
Trimel Announces Issuance of Additional Patent Covering NATESTO(TM)
Marketwired - Tue Nov 25, 12:01PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that its technology partner Mattern Pharma AG has been granted an additional United States Patent in respect of NATESTO(TM) and its proprietary nasal gel technology. Trimel expects one or more claims in such patent to be eligible for listing in the Food and Drug Administration (FDA) Orange Book in connection with NATESTO(TM). The Orange Book is the FDA's database of Approved Drug Products with Therapeutic Equivalence Evaluations.
TRL.TO: 0.43 (-0.02)
